BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25023402)

  • 1. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
    Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
    Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
    Kim G; Jung EJ; Ryu CG; Hwang DY
    Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
    Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
    Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
    Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
    Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
    J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
    Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
    Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
    Thomsen M; Skovlund E; Sorbye H; Bolstad N; Nustad KJ; Glimelius B; Pfeiffer P; Kure EH; Johansen JS; Tveit KM; Christoffersen T; Guren TK
    Br J Cancer; 2018 Jun; 118(12):1609-1616. PubMed ID: 29872151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
    Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
    Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.